ewsba.se
Written by Robert Izquierdo for The Motley Fool->
Vicki Sato sold 22,000 shares on May 1, 2026, generating a transaction value of ~$221,000 at around $10.05 per share.
This trade represented 2% of Sato's direct holdings, reducing her position from 1.10 million to 1,078,391 shares.
All shares were sold from direct ownership; the size of this sale is consistent with Sato's historical cadence of routine liquidity events.
Vicki L. Sato, Chairman of the Board of Directors of Vir Biotechnology (NASDAQ:VIR), reported the sale of 22,000 shares of common stock for a total value of approximately $221,000 according to a SEC Form 4 filing.
Transaction and post-transaction values based on SEC Form 4 weighted average purchase price ($10.05).
* 1-year price change calculated using May 1, 2026 as the reference date.
Vir Biotechnology is a commercial-stage biotechnology company specializing in innovative immunology-based therapies for infectious diseases. The company leverages strategic collaborations and licensing agreements to accelerate product development and expand market reach.
Vir Biotechnology's focus on high-impact viral diseases and robust partnerships positions it as a key player in the infectious disease therapeutics sector.
The May 1 sale of Vir Biotechnology stock by Chairman of the Board of Directors Vicki Sato is not a red flag for investors. The transaction was part of a pre-arranged Rule 10b5-1 trading plan, which is often implemented by insiders to avoid accusations of making trades based on insider information.
Moreover, she retained over one million shares after the sale, maintaining a sizable equity position in the company. Dr. Sato has been Chairman of the Board since 2016. Her long history with Vir Biotechnology suggests she is invested in seeing the company bring its therapies to market.
Shares have done well in 2026, reaching a 52-week high of $11.66 on April 20. This has been due to positive early clinical trial data showing its treatments were effective for patients suffering from prostate cancer.
The company exited the first quarter with a net loss of $125.7 million compared to the prior year’s loss of $121 million. However, it held $809.3 million in cash, cash equivalents and investments at the end of Q1. This should maintain operations for a time while it continues to move its therapies towards government approval for sale.
Before you buy stock in Vir Biotechnology, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vir Biotechnology wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $471,827!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,319,291!*
Now, it’s worth noting Stock Advisor’s total average return is 986% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of May 9, 2026.
Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
This data feed is not available at this time.